Gilead Sciences Inc (GILD)

[slimhere]

Mick, I think we are the only ones watching GILD on iHub, whatever.

I bought more, could have bought better, but what the hay, I feel the sell off was uncalled for on dividend alone, we beat on earning as well as revenues, I believe investors wanted to know why Trodelvy results weren't part of the call, O'Day gave his reasons, he had to be political correct, plus what he said may very well be true; however, the FDA was never efficient but with Covid, they were working remote, hell, they hardly worked when they were at the office, plus, a lot of resources went to studying Covid itself as well as vaccination drugs. That's my nickel take on what's going on, here's what O'Day said.

Gilead CEO Dan O'Day says the delay isn't concerning, and is common in studies that require a certain number of patients to have their cancer worsen before data are analyzed. "Nothing has changed concerning our confidence" in the study's outcome, O'Day says. The delay could be a good sign, assuming Trodelvy patients are taking longer than expected to have their disease worsen. But RBC warns it could also be the control chemotherapy group causing the delay. Trodelvy had 3Q sales of $101M, in line with analyst projections. Trodelvy's sales are projected to be $689M in 2022, and to reach $2.1B in annual sales in 2025.